undamentalytics Newsletter
Sign in

Abvc Biopharma, Inc. income statement

In fiscal 2025, Abvc Biopharma, Inc. reported revenue of $296,000, down 41.9% on the year before, operating income of −$7.2m (a -2416.0% margin) and net income of −$7.9m, or −$0.39 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Sept 20102011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Dec 20152018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue000005001001010
Cost of revenue————0—0000000—
Gross profit————0—−01001−01—
Research and development——————11113100
Selling, general and administrative——————23466523
General and administrative22————————————
Operating income−2−2−1−0——−3−3−9−12−15−7−5−7
Interest expense−00000—00000110
Income before tax——————−6−4−11−11−16−8−5−8
Income tax—000——−0−0−0110−00
Net income−2−1−1−0−0—−6−4−11−13−16−8−5−8
Diluted EPS−$70500.00−$46500.00−$18000.00$0.00−$1.80—−$3.60−$0.21−$0.50−$0.51−$5.19−$1.80−$0.42−$0.39
Diluted shares (average)44m65m64m61m62m—1m2m2m3m3m4m12m20m
EBITDA−2−2−1−0——−3−3−8−12−15−7−5−7

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABVC vs CRDFABVC vs CRVOABVC vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abvc Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abvc Biopharma, Inc.